Financial Information
We introduce ADBIOTECH’s technology intended to replace vaccines
and antibiotics.
Sales
Operating profit
Net profit
Income Statements(Unit: KRW in thousands)
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Sales | 9,343,575 | 9,815,308 | 11,840,173 |
| Cost Of Sales | 4,858,235 | 4,405,101 | 5,012,794 |
| Operating profit | 102,140 | -996,203 | -1,554,598 |
| Non-operating income | 298,735 | 216,651 | 192,479 |
| Non-operating expense | 2,219,731 | 6,696,842 | 1,052,577 |
| Net profit | -1,705,828 | -7,344,923 | -2,664,465 |
Total Assets
Total liabilities
Total equity
Financial Position(Unit: KRW in thousands)
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Current Assets | 5,856,573 | 7,249,143 | 8,672,355 |
| Non-current Assets | 6,058,957 | 11,590,911 | 12,286,989 |
| Total Assets | 11,915,531 | 18,840,054 | 20,959,344 |
| Current liabilities | 12,748,080 | 5,494,861 | 12,625,914 |
| Non-Current liabilities | 70,138 | 4,017,721 | 3,227,821 |
| Total liabilities | 12,818,217 | 9,512,582 | 15,853,735 |
| Share capital | 822,893 | 1,267,337 | 3,846,522 |
| Capital surplus | 2,972,978 | 20,582,470 | 18,292,579 |
| Retained earnings | -6,335,658 | -13,605,996 | -16,270,462 |
| Total equity | -902,687 | 9,327,472 | 5,105,608 |